These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 3496938)
1. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF. Elsworth JD; Deutch AY; Redmond DE; Sladek JR; Roth RH Brain Res; 1987 Jul; 415(2):293-9. PubMed ID: 3496938 [TBL] [Abstract][Full Text] [Related]
2. Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. Elsworth JD; Deutch AY; Redmond DE; Sladek JR; Roth RH Life Sci; 1987 Jan; 40(2):193-202. PubMed ID: 3491946 [TBL] [Abstract][Full Text] [Related]
3. Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine on neostriatal dopamine in mice. Heikkila RE; Cabbat FS; Manzino L; Duvoisin RC Neuropharmacology; 1984 Jun; 23(6):711-3. PubMed ID: 6611514 [TBL] [Abstract][Full Text] [Related]
4. Neurochemical changes in the substantiae nigrae and caudate nuclei following acute unilateral intranigral infusions of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Sirinathsinghji DJ; Whittington PE; Audsley AR Brain Res; 1986 Dec; 399(2):339-45. PubMed ID: 2435361 [TBL] [Abstract][Full Text] [Related]
5. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619 [TBL] [Abstract][Full Text] [Related]
6. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Pifl C; Schingnitz G; Hornykiewicz O Neurosci Lett; 1988 Oct; 92(2):228-33. PubMed ID: 3263594 [TBL] [Abstract][Full Text] [Related]
7. Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys. Di Paolo T; Bédard P; Daigle M; Boucher R Brain Res; 1986 Aug; 379(2):286-93. PubMed ID: 2427166 [TBL] [Abstract][Full Text] [Related]
8. Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease. Sershen H; Hashim A; Lajtha A Pharmacol Biochem Behav; 1987 Oct; 28(2):299-303. PubMed ID: 3500479 [TBL] [Abstract][Full Text] [Related]
9. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration. Pérez-Otaño I; Oset C; Luquin MR; Herrero MT; Obeso JA; Del Río J Neurosci Lett; 1994 Jul; 175(1-2):121-5. PubMed ID: 7970192 [TBL] [Abstract][Full Text] [Related]
11. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys. Elsworth JD; Deutch AY; Redmond DE; Sladek JR; Roth RH Brain Res; 1990 Apr; 513(2):320-4. PubMed ID: 2350702 [TBL] [Abstract][Full Text] [Related]
12. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety. Bradbury AJ; Costall B; Domeney AM; Testa B; Jenner PG; Marsden CD; Naylor RJ Neurosci Lett; 1985 Oct; 61(1-2):121-6. PubMed ID: 2417166 [TBL] [Abstract][Full Text] [Related]
13. Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse. Perry TL; Yong VW; Jones K; Wall RA; Clavier RM; Foulks JG; Wright JM Neurosci Lett; 1985 Aug; 58(3):321-6. PubMed ID: 3876525 [TBL] [Abstract][Full Text] [Related]
14. Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Pifl C; Bertel O; Schingnitz G; Hornykiewicz O Neurochem Int; 1990; 17(2):263-70. PubMed ID: 20504626 [TBL] [Abstract][Full Text] [Related]
15. The effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal and limbic catecholamine neurones in white and black mice. Antagonism by monoamine oxidase inhibitors. Bradbury AJ; Costall B; Jenner PG; Kelly ME; Marsden CD; Naylor RJ Neuropharmacology; 1986 Aug; 25(8):897-904. PubMed ID: 3022182 [TBL] [Abstract][Full Text] [Related]
16. Increase of striatal dopamine turnover by stress in MPTP-treated mice. Urakami K; Masaki N; Shimoda K; Nishikawa S; Takahashi K Clin Neuropharmacol; 1988 Aug; 11(4):360-8. PubMed ID: 3264755 [TBL] [Abstract][Full Text] [Related]
17. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR Neurosci Lett; 1985 Oct; 61(1-2):195-200. PubMed ID: 3878482 [TBL] [Abstract][Full Text] [Related]
18. Behavioral and biochemical changes following acute administration of MPTP and MPP+. Tadano T; Satoh N; Sakuma I; Matsumura T; Kisara K; Arai Y; Kinemuchi H Life Sci; 1987 Mar; 40(13):1309-18. PubMed ID: 2436017 [TBL] [Abstract][Full Text] [Related]
19. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions. Sirinathsinghji DJ; Heavens RP; McBride CS Brain Res; 1988 Mar; 443(1-2):101-16. PubMed ID: 3258784 [TBL] [Abstract][Full Text] [Related]
20. Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys. Falardeau P; Bédard PJ; Di Paolo T Neurosci Lett; 1988 Mar; 86(2):225-9. PubMed ID: 2966905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]